The Cooper Companies, Inc. $COO Stock Bought by Sterling Capital Management LLC

Sterling Capital Management LLC grew its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 198.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,433 shares of the medical device company’s stock after purchasing an additional 11,584 shares during the quarter. Sterling Capital Management LLC’s holdings in Cooper Companies were worth $985,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in COO. Essential Partners LLC boosted its stake in Cooper Companies by 23.4% during the 1st quarter. Essential Partners LLC now owns 874 shares of the medical device company’s stock valued at $62,000 after purchasing an additional 166 shares during the period. SJS Investment Consulting Inc. grew its holdings in Cooper Companies by 107.5% in the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after buying an additional 187 shares during the last quarter. Basecamp Wealth Advisors LLC increased its position in Cooper Companies by 20.8% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 1,557 shares of the medical device company’s stock worth $111,000 after buying an additional 268 shares during the period. 4WEALTH Advisors Inc. increased its position in Cooper Companies by 6.2% in the 1st quarter. 4WEALTH Advisors Inc. now owns 4,714 shares of the medical device company’s stock worth $327,000 after buying an additional 275 shares during the period. Finally, Patton Fund Management Inc. increased its position in Cooper Companies by 10.0% in the 1st quarter. Patton Fund Management Inc. now owns 3,233 shares of the medical device company’s stock worth $231,000 after buying an additional 293 shares during the period. 24.39% of the stock is currently owned by institutional investors.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reaffirmed its fiscal 2026 guidance, signaling that management does not currently expect the leadership transition to alter its financial outlook. The company also appointed healthcare veteran Walt Rosebrough as executive chair; his experience leading medical-device businesses could support operational improvements and shareholder-value initiatives. CooperCompanies Announces Leadership Transition and Board Refreshment
• Positive Sentiment: The planned addition of former Johnson & Johnson medical-device executive Shlomi Nachman and the nomination of a smaller, refreshed seven-member board may improve governance, oversight and strategic execution. CooperCompanies Elects Walt Rosebrough Executive Chair, Announces CEO Search and Board Refreshment
• Neutral Sentiment: Rosebrough is overseeing day-to-day operations while the company searches for a permanent CEO. Outgoing CEO Al White will remain as a strategic adviser through April 2027, which may provide some transition continuity.
• Negative Sentiment: White’s immediate departure as president, CEO and director increases leadership risk. Rosebrough acknowledged that recent performance has fallen short of expectations, potentially reinforcing concerns about the company’s operating momentum and strategy. Cooper Companies CEO White Steps Down
• Negative Sentiment: Rosen Law Firm announced an investigation into potential securities claims alleging that CooperCompanies may have issued materially misleading business information. The announcement does not establish wrongdoing, but it adds legal and reputational risk and may weigh on investor sentiment. Rosen Law Firm Securities Class Action Investigation

Cooper Companies Price Performance

Shares of NASDAQ COO opened at $59.88 on Wednesday. The Cooper Companies, Inc. has a 52-week low of $51.01 and a 52-week high of $89.83. The business has a fifty day moving average of $61.31 and a two-hundred day moving average of $69.45.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. The company’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter last year, the business earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts forecast that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies declared that its board has approved a share repurchase program on Wednesday, September 9th that allows the company to buy back $3 billion in outstanding shares. This repurchase authorization allows the medical device company to buy up to 22.7% of its shares through open market purchases. Share repurchase programs are generally a sign that the company’s board believes its shares are undervalued.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Citigroup reissued a “neutral” rating and issued a $60.00 price objective (down from $80.00) on shares of Cooper Companies in a research report on Thursday, September 10th. Bank of America reaffirmed a “neutral” rating and set a $65.00 target price (down from $80.00) on shares of Cooper Companies in a research report on Thursday, September 10th. Zacks Research cut shares of Cooper Companies from a “hold” rating to a “strong sell” rating in a research note on Friday, September 11th. Wall Street Zen downgraded shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Finally, Barclays raised shares of Cooper Companies to a “hold” rating in a report on Wednesday, October 7th. Four analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $68.60.

Insider Transactions at Cooper Companies

In other Cooper Companies news, Director Walter M. Rosebrough, Jr. purchased 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was purchased at an average cost of $54.29 per share, with a total value of $162,870.00. Following the acquisition, the director directly owned 20,000 shares of the company’s stock, valued at approximately $1,085,800. This trade represents a 17.65% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Paul A. Keel purchased 4,701 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The shares were acquired at an average cost of $53.18 per share, with a total value of $249,999.18. Following the completion of the acquisition, the director directly owned 4,701 shares in the company, valued at approximately $249,999.18. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 34,701 shares of company stock valued at $1,880,039. Corporate insiders own 2.08% of the company’s stock.

Cooper Companies Company Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.